NasdaqGS - Nasdaq Real Time Price USD

Werewolf Therapeutics, Inc. (HOWL)

Compare
1.3800
-0.0600
(-4.17%)
At close: January 10 at 4:00:02 PM EST
1.3500
-0.03
(-2.17%)
After hours: January 10 at 6:44:36 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,386.0000
19,943.0000
16,401.0000
--
--
Operating Expense
69,594.0000
60,446.0000
72,457.0000
50,087.0000
22,404.0000
Operating Income
-66,208.0000
-40,503.0000
-56,056.0000
-50,087.0000
-22,404.0000
Net Non Operating Interest Income Expense
2,940.0000
4,277.0000
1,908.0000
104.0000
63.0000
Other Income Expense
1,150.0000
-1,142.0000
338.0000
--
7,301.0000
Pretax Income
-62,118.0000
-37,368.0000
-53,810.0000
-49,983.0000
-15,040.0000
Net Income Common Stockholders
-63,528.0000
-37,368.0000
-53,810.0000
-201,925.0000
-28,217.0000
Diluted NI Available to Com Stockholders
-63,528.0000
-37,368.0000
-53,810.0000
-201,925.0000
-28,217.0000
Basic EPS
-1.50
-1.05
-1.86
-10.94
-3.15
Diluted EPS
-1.52
-1.05
-1.86
-10.94
-3.15
Basic Average Shares
41,355.5690
35,646.5720
28,864.0000
18,455.0000
8,970.7320
Diluted Average Shares
41,684.8230
35,646.5720
28,864.0000
18,455.0000
8,970.7320
Total Operating Income as Reported
-66,208.0000
-40,503.0000
-56,056.0000
-50,087.0000
-22,404.0000
Total Expenses
69,594.0000
60,446.0000
72,457.0000
50,087.0000
22,404.0000
Net Income from Continuing & Discontinued Operation
-62,118.0000
-37,368.0000
-53,810.0000
-49,983.0000
-15,040.0000
Normalized Income
-61,565.0000
-37,368.0000
-53,810.0000
-49,983.0000
-15,040.0000
Interest Income
7,339.0000
7,416.0000
1,908.0000
104.0000
63.0000
Interest Expense
4,399.0000
3,139.0000
--
--
--
Net Interest Income
2,940.0000
4,277.0000
1,908.0000
104.0000
63.0000
EBIT
-57,719.0000
-34,229.0000
-53,810.0000
-50,087.0000
-22,404.0000
EBITDA
-55,887.0000
-32,465.0000
-52,706.0000
-49,871.0000
-22,254.0000
Reconciled Depreciation
1,832.0000
1,764.0000
1,104.0000
216.0000
150.0000
Net Income from Continuing Operation Net Minority Interest
-62,118.0000
-37,368.0000
-53,810.0000
-49,983.0000
-15,040.0000
Total Unusual Items Excluding Goodwill
-553.0000
--
--
--
--
Total Unusual Items
-553.0000
--
--
--
--
Normalized EBITDA
-55,334.0000
-32,465.0000
-52,706.0000
-49,871.0000
-22,254.0000
12/31/2020 - 4/30/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

XLO Xilio Therapeutics, Inc.
1.1000
-1.79%
 
ELEV Elevation Oncology, Inc.
0.6504
-13.72%
 
PRLD Prelude Therapeutics Incorporated
1.0600
-7.02%
 
IKNA Ikena Oncology, Inc.
1.5600
-2.50%
 
DSGN Design Therapeutics, Inc.
4.5200
-10.94%
 
NKTX Nkarta, Inc.
2.3500
-1.67%
 
INAB IN8bio, Inc.
0.3233
+3.42%
 
ALXO ALX Oncology Holdings Inc.
1.7700
-4.32%
 
BCAB BioAtla, Inc.
0.5316
-5.07%
 
IPSC Century Therapeutics, Inc.
0.9900
-7.48%